Core Viewpoint - Perfectech International (00765) announced that the conditions for its rights issue have been fulfilled, making the rights issue unconditional as of November 28, 2025 [1] Summary by Relevant Sections - The effective acceptance of provisional allotment notices totaled 17 applications, involving 97.3036 million shares, which is approximately 59.53% of the total 163 million shares available for subscription under the rights issue [1] - For the excess application forms, there were 7 applications received, totaling 77.6445 million shares, representing about 47.50% of the total shares available for subscription [1] - In total, there were 24 valid acceptances and applications for a combined 175 million shares, which is approximately 107.03% of the total shares available for subscription [1] - The rights issue was oversubscribed by 11.4864 million shares, equating to about 7.03% of the total shares available for subscription [1]

智通财经APP讯，PERFECTECH INTL(00765)发布公告，由于供股章程所载有关供股的所有条件已获达 成，故供股已于2025年11月28日(星期五)下午四时正成为无条件。 于合并计算后，就暂定配额通知书及超额申请表格项下合共1.75亿股供股股份接获24份有效接纳及有效 申请，相当于供股项下合共可供认购的1.63亿股供股股份约107.03%。 根据上述结果，供股获超额认购1148.64万股供股股份，相当于供股项下合共可供认购的1.63亿股供股股 份约7.03%。 于2025年11月28日(星期五)下午四时正(即接纳供股股份及缴付股款以及申请超额供股股份及缴付股款的 最后时限)：就暂定配额通知书项下暂定配额接获的有效接纳合共17份，合共涉及9730.36万股供股股 份，相当于供股项下合共可供认购的1.63亿股供股股份约59.53%;及就超额申请表格项下超额供股股份 接获的有效申请合共7份，合共涉及7764.45万股超额供股股份，相当于供股项下合共可供认购的1.63亿 股供股股份约47.50%。 ...

Core Viewpoint - Crown Global Group (00727.HK) announced a proposed rights issue, offering three (3) new shares for every one (1) existing share held at a subscription price of HKD 0.65 per share, representing a discount of approximately 19.75% to the closing price of HKD 0.81 on the Hong Kong Stock Exchange [1] Summary by Category - **Rights Issue Details** - The rights issue aims to raise a total of up to approximately HKD 620 million before expenses, assuming no change in the number of shares issued as of the record date [1] - The estimated net proceeds from the rights issue, after deducting all necessary expenses, are expected to be around HKD 618 million [1] - **Eligibility and Participation** - The rights issue is only available to qualifying shareholders, and ineligible shareholders will not be able to participate [1]

Core Viewpoint - Yongtai Bio-B (06978) has announced significant oversubscription in its rights issue, indicating strong investor interest and confidence in the company's future prospects [1][2] Group 1 - The company received valid acceptances for a total of 92.1758 million rights shares, representing approximately 89.56% of the total 103 million rights shares offered [1] - There were 8 valid applications for additional rights shares, totaling 446 million shares, which is about 433.15% of the total rights shares offered [1] - In total, there were 21 valid acceptances and applications for 538 million rights shares, amounting to approximately 522.71% of the total rights shares offered [1] Group 2 - A total of 435 million rights shares were oversubscribed, which is about 422.71% of the total 103 million rights shares offered [2] - The allocation of additional rights shares was made based on a ratio of approximately 2.41% of the number of additional shares applied for, due to insufficient shares to meet all valid applications [2] - There was no prioritization for applications based on existing shareholdings or for consolidating fractional shares into whole shares [2]

Group 1 - The company, Yu Neng Holdings (00442), announced a rights issue where eligible shareholders will receive 1 share for every 2 existing shares held, at a subscription price of HKD 0.710 per share [1] - The rights issue aims to raise a maximum net amount of approximately HKD 61 million by issuing up to 86.35 million shares, assuming no changes in the number of shares issued prior to the record date [1] - As of March 31, 2025, the company reported cash and bank balances of approximately HKD 36.3 million, indicating a cautious financial strategy to strengthen its financial position and support future business development through the rights issue [1]

Core Viewpoint - The recent stock transfer of Ying Sheng Science (00209) indicates a significant movement in shareholder interests, coinciding with the company's proposed rights issue to raise capital [1] Group 1: Stock Transfer - On November 7, Ying Sheng Science's shareholders transferred shares from Li Hing Stock to Yao Cai Securities, with a transfer market value of HKD 3.7566 million, accounting for 8.09% of the total shares [1] Group 2: Rights Issue - Ying Sheng Science announced a proposed rights issue, offering 7 new shares for every existing share held at a subscription price of HKD 0.14 per share [1] - The company aims to issue up to approximately 1.3 billion new shares, assuming no changes in the number of shares issued as of the record date, to raise a total of approximately HKD 182 million [1]

Core Viewpoint - The recent transfer of shares for Ying Sheng Science (00209) indicates a strategic move by shareholders, coinciding with the company's proposed rights issue to raise capital [1] Group 1: Shareholder Activity - On November 6, shareholders of Ying Sheng Science transferred shares from Futu Securities International Hong Kong to Wutong Securities, with a market value of HKD 8.1286 million, representing 14.35% of the total shares [1] Group 2: Company Announcement - Ying Sheng Science announced a rights issue proposal, offering 7 new shares for every existing share held at a subscription price of HKD 0.14 per share [1] - The company aims to issue up to approximately 1.3 billion new shares, assuming no changes in the number of shares issued as of the record date, to raise a total of approximately HKD 182 million [1]

Core Viewpoint - The recent transfer of shares for Ying Sheng Science (00209) indicates a strategic move by shareholders, with a significant portion of shares being moved to a different brokerage, potentially reflecting investor sentiment and market positioning [1] Group 1: Shareholder Activity - On November 6, shareholders of Ying Sheng Science transferred shares from Futu Securities International Hong Kong to Wutong Securities, with a total market value of HKD 8.1286 million, accounting for 14.35% of the company's shares [1] Group 2: Corporate Actions - Ying Sheng Science announced a proposed rights issue, offering 7 new shares for every existing share held at a subscription price of HKD 0.14 per share [1] - The company aims to raise a maximum of approximately HKD 182 million through the issuance of up to 1.3 billion rights shares, assuming no changes in the number of shares issued as of the record date [1]

Core Viewpoint - 惠陶集团 plans to issue up to 261 million shares through a rights issue at a subscription price of HKD 0.20 per share, aiming to raise approximately HKD 52.25 million before expenses [1] Group 1: Rights Issue Details - The rights issue will be based on a ratio of 3 new shares for every 1 share held by eligible shareholders on the record date [1] - The estimated net proceeds from the rights issue will be approximately HKD 49.44 million [1] - The subscription price represents a discount of about 6.98% compared to the last closing price of HKD 0.215 per share on the Stock Exchange [1] Group 2: Offering Structure - The rights issue will be conducted on a non-underwritten basis, meaning there will be no additional application arrangements for shareholders [1] - The rights issue will not be presented to excluded shareholders [1]

Core Points - Huatai UBS (08006) announced that as of October 13, 2025, it received a total of 33 valid applications for a rights issue, involving 93.7938 million shares, which represents approximately 42.4% of the total shares offered in the rights issue [1] - The rights issue was not fully subscribed, resulting in a shortfall of 128 million shares, accounting for about 57.6% of the total shares offered, which will be handled according to the compensation arrangement [1] - By the deadline of October 28, 2025, all 128 million unsubscribed shares and shares not sold by excluded shareholders were successfully placed at a price of HKD 0.08 per share, equivalent to the subscription price, leading to no net proceeds available for distribution to non-participating shareholders [1] - The total amount raised from the rights issue, including the placement, was approximately HKD 17.7 million, with a net amount of about HKD 16.6 million after expenses [1]